ImmunityBio Says FDA Widened Anktiva's Label To Papillary-Only Bladder Cancer, A Group It Puts At About 85% Of Patients

The company says it is the first FDA approval covering papillary-only tumors in BCG-unresponsive disease, resting on earlier data from carcinoma in situ patients.

Share
ImmunityBio Says FDA Widened Anktiva's Label To Papillary-Only Bladder Cancer, A Group It Puts At About 85% Of Patients

ImmunityBio said the FDA has expanded the approved use of its bladder cancer drug Anktiva, used with BCG, to cover patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) who have papillary-only tumors. The company disclosed the approval in an 8-K and a press release dated Wednesday.

What the label now covers

The new label reads that Anktiva, with Bacillus Calmette-Guérin (BCG), is indicated for adults with BCG-unresponsive non-muscle invasive bladder cancer. It builds on the FDA's April 2024 approval for patients with carcinoma in situ (CIS), with or without papillary tumors.

ImmunityBio called this the first FDA approval to include BCG-unresponsive NMIBC with papillary-only tumors. That is the company's claim, made in its release.

The company said papillary disease makes up approximately 85% of the NMIBC patient population. A separate line in the release, citing a 2019 conference presentation, puts the share of newly diagnosed NMIBC patients who present with papillary disease at 85% to 90%. The release says the expansion "significantly increases" Anktiva's U.S. addressable population.

The evidence behind it

The company said the approval rests on the FDA's review of available scientific information, including efficacy already shown in CIS patients. In Cohort A of the QUILT-3.032 trial, 62% of 77 patients had a complete response. Among responders, 58% kept it for at least 12 months and 40% for at least 24 months.

The release describes a tolerable safety profile, with most common treatment-related side effects tied to bladder instillation, such as dysuria, pollakiuria and hematuria, and mostly grade 1 to 2. The prescribing information warns that delaying cystectomy (bladder removal) can lead to metastatic bladder cancer, which can be lethal.

CEO Richard Adcock said in the release that the expansion "broadens the eligible patient population." Executive Chairman Patrick Soon-Shiong called it "an important first step as we develop immunotherapy 2.0."

Timing and what to watch

According to Yahoo Finance, the decision came months ahead of a January 6 FDA target date, and the agency leaned on similarities between CIS and high-grade papillary tumors.

ImmunityBio shares closed at $9.91 on Wednesday and traded at $9.99 in Wednesday after-hours trading, before the 5:19 p.m. ET filing.

Soon-Shiong is slated to speak at a Piper Sandler oncology symposium fireside chat on Friday, per Yahoo Finance, where bladder cancer is expected to come up.

The company's own risk language says the number of eligible patients may turn out smaller than it anticipates, so uptake is the figure to follow.

Sources